Replies to post #17693 on Radient Pharmaceuticals Corporation fka RXPC

[lakeshore555]

RXPC is not a fraud.

Radient got a device cleared by the FDA. They tried to sell it. They failed.

That's not fraud. That's just a failed company.

Radient actually turned a profit one quarter because of Jade. However, Radient no longer has Jade as an asset. Therein lies the main reason for Radient's failure. The previous CEO Dreher was moving away from DR-70 and focusing on Jade, but the current CEO MacLellan did not maintain a good relationship with Jade and was forced to re-focus on DR-70 sales when Jade left in 2009.

Unfortunately, the global medical community did not embrace DR-70, and Radient could not repay their loans. Fast-forward to today: Defaulted loans, multi-million-dollar debt, dilution to 5 billion shares, brick-and-mortar doors closed, Officers all gone except for the CEO and one new guy from the CEO's failed past, and the only plum in the fruit basket, Asia Sales, given to UNI for $100,000 per year.

The only fraud lies in misrepresenting this company as having a future and/or perpetuating a false rumor that the company will be bought, taken over, or merged with. Radient officers are not doing that.

The "Mayo Study" PR's may or may not constitute fraud. A jury will decide that in November. I don't expect Radient Pharmaceuticals Corporation to exist by that time. I expect bankruptcy before then because Radient does not have funds for trial lawyers. Even if they cashed out that last 500 million shares for legal fees, it would not come close to paying for trial lawyers.